Clinical Trial Update: Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the sustained-release formulation DVS-233 SR for vasomotor symptoms in menopause has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause

Drugs mentioned

• DVS-233 SR

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Menopause | Phase 3 | Status: COMPLETED